These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 29339252)
21. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma. Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487 [TBL] [Abstract][Full Text] [Related]
22. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors. Maccari R; Ettari R; Adornato I; Naß A; Wolber G; Bitto A; Mannino F; Aliquò F; Bruno G; Nicolò F; Previti S; Grasso S; Zappalà M; Ottanà R Bioorg Med Chem Lett; 2018 Feb; 28(3):278-283. PubMed ID: 29292224 [TBL] [Abstract][Full Text] [Related]
23. Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death. Tanaka M; Zhu Y; Shionyu M; Ota N; Shibata N; Watanabe C; Mizusawa A; Sasaki R; Mizukami T; Shiina I; Hasegawa M Eur J Med Chem; 2018 Feb; 146():636-650. PubMed ID: 29407987 [TBL] [Abstract][Full Text] [Related]
24. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes. Xin BT; de Bruin G; Huber EM; Besse A; Florea BI; Filippov DV; van der Marel GA; Kisselev AF; van der Stelt M; Driessen C; Groll M; Overkleeft HS J Med Chem; 2016 Aug; 59(15):7177-87. PubMed ID: 27438186 [TBL] [Abstract][Full Text] [Related]
25. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation. Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors. Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990 [TBL] [Abstract][Full Text] [Related]
27. Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents. Almaliti J; Miller B; Pietraszkiewicz H; Glukhov E; Naman CB; Kline T; Hanson J; Li X; Zhou S; Valeriote FA; Gerwick WH Eur J Med Chem; 2019 Jan; 161():416-432. PubMed ID: 30384045 [TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors. Xu K; Xiao Z; Tang YB; Huang L; Chen CH; Ohkoshi E; Lee KH Bioorg Med Chem Lett; 2012 Apr; 22(8):2772-4. PubMed ID: 22437113 [TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids. Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867 [TBL] [Abstract][Full Text] [Related]
30. Cupriphilic compounds to aid in proteasome inhibition. Mukherjee S; Sparks R; Metcalf R; Brooks W; Daniel K; Guida WC Bioorg Med Chem Lett; 2016 Aug; 26(15):3826-9. PubMed ID: 27311892 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome. Momose I; Umezawa Y; Hirosawa S; Iijima M; Iinuma H; Ikeda D Biosci Biotechnol Biochem; 2005 Sep; 69(9):1733-42. PubMed ID: 16195592 [TBL] [Abstract][Full Text] [Related]
32. Linear TMC-95-based proteasome inhibitors. Basse N; Piguel S; Papapostolou D; Ferrier-Berthelot A; Richy N; Pagano M; Sarthou P; Sobczak-Thépot J; Reboud-Ravaux M; Vidal J J Med Chem; 2007 Jun; 50(12):2842-50. PubMed ID: 17511440 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors. Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683 [TBL] [Abstract][Full Text] [Related]
34. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer. Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533 [TBL] [Abstract][Full Text] [Related]
35. Development of peptidomimetic boronates as proteasome inhibitors. Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651 [TBL] [Abstract][Full Text] [Related]
36. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214 [TBL] [Abstract][Full Text] [Related]
37. Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors. Cheemanapalli S; Anuradha CM; Madhusudhana P; Mahesh M; Raghavendra PB; Kumar CS Anticancer Agents Med Chem; 2016; 16(11):1496-1510. PubMed ID: 27173965 [TBL] [Abstract][Full Text] [Related]
38. [Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome]. Ma YH; Xu B; Cui JR; Yang ZJ; Zhang LR; Zhang LH Yao Xue Xue Bao; 2012 Apr; 47(4):472-8. PubMed ID: 22799029 [TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening. Miller Z; Kim KS; Lee DM; Kasam V; Baek SE; Lee KH; Zhang YY; Ao L; Carmony K; Lee NR; Zhou S; Zhao Q; Jang Y; Jeong HY; Zhan CG; Lee W; Kim DE; Kim KB J Med Chem; 2015 Feb; 58(4):2036-41. PubMed ID: 25658656 [TBL] [Abstract][Full Text] [Related]